Navigation Links
PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
Date:2/24/2009

ANNAPOLIS, Md., Feb. 24 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Alternext US: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that results from a Phase II study of SparVax(TM) and pharmacokinetic (PK) data for Valortim(R) were presented at the 7th Annual ASM Biodefense and Emerging Diseases Research Meeting, being held in Baltimore, MD, February 22-25, 2009.

David P. Wright, President and Chief Executive Officer of PharmAthene commented, "The ASM conference is among the leading industry meetings of the year for biodefense and we are pleased to be able to showcase advancements in each of our SparVax(TM) and Valortim(R) programs to key policy makers at this important meeting."

"PharmAthene has received tremendous support from a variety of government funding partners, including, the Department of Defense, the Department of Health and Human Services, and the National Institute of Allergy and Infectious Diseases. This unprecedented collaborative effort will help to ensure the development of urgently needed medical countermeasures to meet the biosecurity needs of our Nation and Allies."

SparVax(TM) is a novel second generation recombinant protective antigen (rPA) anthrax vaccine that is being developed for pre and post exposure protection against anthrax infection. Valortim(R), in co-development with Medarex, Inc. (Nasdaq: MEDX), is a fully human monoclonal antibody designed to protect against and treat inhalational anthrax, the most lethal form of illness in humans caused by anthrax.

SparVax(TM) Phase II Clinical Data

Results from a Phase II clinical trial of SparVax(TM) were presented during a poster session by Dr. Matthew Duchars, Chief Scientific Officer for PharmAthene. The Phase II trial was designed t
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
2. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
3. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
4. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
5. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
6. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
7. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
8. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
9. PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
10. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
11. PharmAthene Reports Second Quarter 2008 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MESA, Calif. , July 24, 2014  Now ... close to home. Rehealth Regenerative Therapies , located ... athletes and other physically active people a new health ... Regardless of age, countless patients suffer from ... sport activities, such as muscle tears, torn rotator cuff, ...
(Date:7/24/2014)... have yet to materialise. Yet, scientists are making ... computers faster. One such approach relies on quantum ... applying an electric field. A new study demonstrates ... quantum dots (TQDs) with electrical impulses can help ... should TQDs be used as quantum information units, ...
(Date:7/24/2014)... California (PRWEB) July 24, 2014 ... to advances in modeling lithium-ion battery storage capacity. ... benefit from a theoretical model created at ... University that predicts how carbon components will ... energy storage emphasizes the urgent need for higher-performance ...
(Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... forecasts of its potential revenue from new rodenticide research ... investors and analysts on July 22, 2014, Neogen,s CEO ... regarding this research. "It was my intent ... the potential of a new type of rodenticide, but ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Getting More Life out of Lithium-ion Batteries 2Neogen comments on SenesTech 2
... -- JERUSALEM and NEEDHAM, Massachusetts, August 18, 2010, ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in ...
... Fuels, Inc., a company focused on commercially producing low-carbon ... has produced cellulosic methanol from the initial phase of ... using non-food biomass. The first phase of ... thermo-chemical process, which uses heat, pressure, and steam to ...
... VANCOUVER, Canada, Aug. 17 Xenon Pharmaceuticals Inc. announced ... trial evaluating its novel topical XEN402 therapy for the ... developed by Xenon as a topical ointment formulation and ... 1 study in normal human volunteers.  The product was ...
Cached Biology Technology:Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 2Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 3Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 4Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 5Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 6Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 7Range Fuels Produces Cellulosic Methanol From First Commercial Cellulosic Biofuels Plant 2Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402. 2
(Date:7/25/2014)... online in the International Journal of Cancer ... cervical cancer based on findings showing successful reduction in ... discrete population of cells in the cervix. , ... squamocolumnar junction cells, or SCJ cells. These cells reside ... the origins of cervical cancer. A research team co-led ...
(Date:7/25/2014)... consume the healthcare community and remain priority ... To address the worldwide crisis of obesity ... global leaders in diabetes, epidemiology and public ... and development of diverse intervention programs in ... This book on "Global Health Perspectives in ...
(Date:7/25/2014)... is a complex congenital central nervous system disease ... the neural tubes during the embryonic phase. Many ... fecal incontinence and neurocognitive retardation. Such problems decrease ... life. Researchers at Ankara Physical Medicine and Rehabilitation ... performance in children with SB, using the Pediatric ...
Breaking Biology News(10 mins):Clearing cells to prevent cervical cancer 2What constitutes an effective response to the global 'diabesity' tsunami? 2
... Emory University's Winship Cancer Institute have identified a novel ... role the marker may play when the tumor spreads ... is elevated in the cerebrospinal fluid of patients with ... in the November issue of Clinical Cancer Research. ...
... that an old and relatively unpopular theory about how a ... accurate after all, and acting in nature. , The finding, ... reassess the process involved in the origin of species. The ... genes that change their locations in a genome. , "In ...
... boost the production of a gassy chemical messenger to dilate ... in unmasking cancer cells so that the immune system can ... Kimmel Cancer Center. , Tests at Hopkins on mice with ... two- and threefold in sildenafil-treated animals, compared to mice that ...
Cached Biology News:Newly identified biomarker detects and regulates spread of brain tumors 2Genetic surprise confirms neglected 70-year-old evolutionary hypothesis 2Genetic surprise confirms neglected 70-year-old evolutionary hypothesis 3'Erectile dysfunction' drugs heighten natural anti-cancer activity 2
... The ProteinChip Antibody Capture ... development and optimization steps ... antibody-antigen interactions. This kit ... differentiation of multiple antigens ...
...
... CLS number is a new product ... product number. If showing no availability ... Sigma-Aldrich number (R4276) or contact customer ... polystyrene (expanded surface, easy grip) ...
... Services offer a full range of peptide ... Services include: Peptide synthesis, crude product ... synthesis, purified product (70-95% pure) ... fluorescein, myristylation, phosphorylation, and rhodamine) ...
Biology Products: